All News

FDA%20approved2.jpg

FDA Approves Obinutuzumab for Active Lupus Nephritis

Jack Cush, MD

The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.

Read Article
RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
lupus_0.jpg

Telitacicept Effective in Systemic Lupus Erythematosus

Jack Cush, MD

The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.

Read Article
RheumNow Podcast square

Eating Crow (10.10.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
dna

Sequencing DNA to find new lupus treatments

EurekAlert!

Medical University of South Carolina geneticist Betty Tsao, Ph.D., will lead a five-year project to identify rare mutations associated with childhood-onset systemic lupus erythematosus (SLE), or lupus, with more than $3.5 million in funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Tsao holds the Richard M. Silver Endowed Chair for Inflammation Research in the Division of Rheumatology and Immunology at MUSC.

Read Article
RheumNow Podcast square

How Does Your Garden Grow (9.26.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA. 

Read Article
Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/lwq8ZUMTQ8
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of biopsy proven lupus nephritis pts (1970-2024) - a total of 324 LN pts followed for median 9.9 yrs -- 30 (9.3%) developed Venous Thromboembolic event (VTE); time from LN to 1st VTE 4.4 yrs. Predictors were SLEDAI-2K score (HR= 1.05) and proteinuria level (HR 1.26)

Dr. John Cush RheumNow ( View Tweet)

Failure of IL-17 inhibition in Lupus nephritis. 31 LN pts enrolled in phase 2 DBRPCT of secukinumab 300 mg IV, but was terminated early for futility (complete renal response at week 52 was lower with secukinumab (24.2%) than with placebo (36.3%). https://t.co/471TolqtFk https://t.co/gKi2Z2MZHS

Links:

Dr. John Cush RheumNow ( View Tweet)

Osteonecrosis: suspect with trauma, high-dose steroids, alcoholism, renal failure, transplantation, SLE, thrombotic states (e.g., sickle cell anemia, hemoglobinopathies), radiation injury, pancreatitis, gout, pregnancy, hyperlipidemia, & caisson disease (decompression sickness) https://t.co/y6iYd5fWZ2

Dr. John Cush RheumNow ( View Tweet)
Multimorbidity in SLE: metanalysis of 3 studies (1175 pts) saw Multimorbidity (by higher Charlson comorbidity index/CCI), is a strong independent predictor of mortality in SLE (OR 3.92). In SLE, the most freq comorbidities were DM, CVD, COPD, renal/lung/CNS Dz https://t.co/fuYUdfC6wE
Dr. John Cush RheumNow ( View Tweet)
Sequencing DNA to find new lupus treatments MUSC geneticist Betty Tsao, Ph.D., will lead a five-year project to identify rare mutations associated with childhood-onset SLE, or lupus, with more than $3.5 million in funding from the National Institute of Arthritis and https://t.co/1vfQ4fK6FX
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. https://t.co/wG2Qrn1PSU https://t.co/gP8XYO4q92

Links:

Dr. John Cush RheumNow ( View Tweet)
TREG EULAR 2025 - Review of SLE & Autoimmune Rheumatic Diseases (AIRD) https://t.co/8Em6Dp0oL5 via @YouTube

Links:

Dr. John Cush RheumNow ( View Tweet)

Report of 54 Sjögren dz pts w/ cutaneous vasculitis (CV); most had cryoglobulinemic vasculitis & hypergammaglob.vasculitis. Sjogrens w/ CV had higher risk of lymphoma. Type II cryoglob. vasculitis incr risk of mortality/lymphoma, renal dz, peripheral nerve involvement https://t.co/Yd1iu9ZJX0
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: ILD with Positive SSA and Rash Dr. Elena Joerns, Rochester, Minnesota discusses a case of ILD with positive SSA and rash, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/Yuz8CuIN5H https://t.co/3M9emsIXVf

Links:

Dr. John Cush RheumNow ( View Tweet)
CAR-T Product Shows Early Promise in Lupus Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months. https://t.co/eg37PZK6kn
Dr. John Cush RheumNow ( View Tweet)
Inception SLE study of 674 pts (without LN), mean age 34 yrs - 154 (23%) developed new proteinuria (LN) after median of 3.6 yr. Cumulative antimalarial exposure did NOT lower risk of LN (HR 0.98; 0.94-1.02); same for those w/ serologically active SLE (HR 0.97) https://t.co/8OU3yJAvhN
Dr. John Cush RheumNow ( View Tweet)
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×